Hong Kong Chinese medicine push hinges on digital, talent fixes

Subsidised outpatient slots at CMHHK were filled in the opening month.

Hong Kong’s first dedicated Chinese medicine hospital has drawn strong patient demand, but gaps in digital integration, workforce planning and research commercialisation could limit its expansion, analysts said.

Subsidised outpatient appointments at the 400-bed Chinese Medicine Hospital of Hong Kong (CMHHK), which opened in December 2025, were fully booked in its first month shortly after reservations began.

The government later doubled quotas for the first 10 days of service and raised remaining monthly slots by 30% to meet demand.

The early surge underscores the appetite for institutionalised Chinese medicine. Yet the longer-term test lies in whether the hospital can anchor a more integrated system that links clinics, laboratories and the industry.

Only a small fraction of Hong Kong’s roughly 10,700 registered Chinese medicine practitioners are connected to electronic health record systems, said Ryan Ip, vice president of Our Hong Kong Foundation.

“Workflow design and system integration also need to be optimised,” he said in an emailed reply to questions. “We recommend increasing promotion and engaging professionals to address practical concerns before gradually making eHealth participation mandatory.”

Ip added that low public understanding and limited cross-disciplinary awareness may slow adoption, requiring targeted education to improve confidence and appropriate use.

Without broader digital connectivity, patient data may remain fragmented, limiting coordination with Western medical providers and constraining clinical research.

Rathanesh Ramasundram, director for healthcare and life sciences at Frost & Sullivan, Inc., said the hospital’s ability to fully use its bed capacity and clinical trial facilities would be critical.

She also cited the need for structured links between CMHHK, Western hospitals and community clinics to support integrated care models.

Next door, the Government Chinese Medicines Testing Institute (GCMTI) is developing testing and quality standards for Chinese medicine products.

“These institutions will likely turn Hong Kong’s Chinese medicine sector from a mainly outpatient, small-clinic model into a more integrated 'hospital–lab–industry' ecosystem,” Ramasundram said in an emailed reply to questions.

Commercial translation remains a weak link. Whilst research and standard-setting may strengthen clinical credibility, mechanisms to convert findings into exportable products are limited, Ip said.

“We recommend creating a joint research platform, including a commercialisation office, to help bring CMHHK and GCMTI’s findings to market, along with stronger trade and intellectual property protections,” he added.

Clinical collaboration is focusing on areas such as stroke rehabilitation and cancer care, where Chinese medicine is positioned as complementary to conventional treatment, Ip said. Mental health, particularly sleep and stress-related conditions, might also offer room for expansion, he added.

Workforce constraints could pose another bottleneck. A 2020 Health Manpower Survey showed most responding practitioners worked in the private sector, though participation rates were low.

Ip called for a comprehensive manpower review, licensing reform with practical clinical examinations, and stronger cross-disciplinary training.

Expanding integrated care will require more doctors trained in both systems. CMHHK has been tasked with training Western practitioners in Chinese medicine and supporting integrated centres.

“In five years, this could create a strong base of practitioners who can operate in hospital-grade Chinese medicine and integrated settings,” Ramasundram said.